Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
City of Hope, Duarte, California University of California, San Francisco, San Francisco, California John Hopkins University, Baltimore, Maryland University of Minnesota, Minneapolis, Minnesota Weill Cornell Medicine, New York, New York UPMC, Pittsburgh, Pennsylvania University of Texas MD Anderson Cancer Center, Houston, Texas Fred Hutchinson Cancer Center, Seattle, Washington Age range
18 Years and older
Last updated October 2025